Shanghai Xitali Biopharmaceutical Technology

Shanghai Xitali Biopharmaceutical Technology is a biopharmaceutical company focused on the discovery and development of next-generation protein degradation therapies. Utilizing its proprietary X-Deg and X-Glue platforms, the company designs small molecules, including PROTACs and molecular glues, to target disease-causing proteins in oncology and immunology. Xitali aims to overcome the limitations of traditional inhibitors by enabling the degradation of "undruggable" targets. The company is based in Shanghai and operates within the Zhangjiang Hi-Tech Park ecosystem. It was founded in 2021 by industry veterans with expertise in medicinal chemistry and drug discovery.